Danaher Co. (NYSE:DHR) Shares Bought by Sargent Investment Group LLC

Sargent Investment Group LLC lifted its position in shares of Danaher Co. (NYSE:DHR) by 30.6% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 11,252 shares of the conglomerate’s stock after acquiring an additional 2,635 shares during the period. Sargent Investment Group LLC’s holdings in Danaher were worth $2,811,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Oak Thistle LLC acquired a new stake in Danaher during the 2nd quarter valued at $363,000. Caden Capital Partners LP increased its position in Danaher by 12.4% during the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock worth $32,172,000 after purchasing an additional 15,313 shares in the last quarter. JARISLOWSKY FRASER Ltd raised its stake in Danaher by 10.8% in the 4th quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after purchasing an additional 55,908 shares during the last quarter. HighPoint Advisor Group LLC purchased a new position in shares of Danaher during the fourth quarter valued at approximately $2,614,000. Finally, Norden Group LLC acquired a new stake in Danaher during the first quarter worth approximately $4,151,000. 79.05% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Danaher

In other news, SVP Georgeann Couchara sold 952 shares of Danaher stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the transaction, the senior vice president now owns 4,212 shares in the company, valued at approximately $1,130,374.44. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the firm’s stock in a transaction dated Thursday, July 25th. The shares were sold at an average price of $275.16, for a total value of $2,641,536.00. Following the transaction, the senior vice president now owns 20,230 shares of the company’s stock, valued at $5,566,486.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at $1,130,374.44. The disclosure for this sale can be found here. Insiders have sold 39,659 shares of company stock worth $11,042,433 over the last quarter. 11.10% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the stock. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Wells Fargo & Company initiated coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. Bank of America upped their price target on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Jefferies Financial Group started coverage on Danaher in a research note on Monday, June 3rd. They issued a “buy” rating and a $295.00 price objective on the stock. Finally, Stifel Nicolaus raised their target price on shares of Danaher from $235.00 to $250.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Seven research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Price Performance

DHR stock opened at $276.06 on Tuesday. The stock’s 50 day moving average is $265.25 and its two-hundred day moving average is $256.67. Danaher Co. has a 52-week low of $182.09 and a 52-week high of $281.70. The company has a market capitalization of $199.37 billion, a PE ratio of 46.79, a P/E/G ratio of 4.48 and a beta of 0.83. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.57 by $0.15. The business had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s revenue was down 2.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.05 earnings per share. Analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Friday, September 27th will be issued a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.39%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.